SIRUM Brings Non-profit, Home-delivery Pharmacy, Good Pill, to Illinois
In 2011, the opioid crisis reached astounding levels with over 21,000 deaths adding to the urgency of providing aid to those who most need it
Charitable Pharmacies of America organization member receives Health Equity grant
We estimate that if the PHE expires in April 2023, 18.0 million people will lose Medicaid coverage in the following…
How is a charitable pharmacy different from other types of pharmacies?
Just as banks have helped seniors bridge the digital divide and leverage online banking to better manage their money, healthcare organizations need to help older adults leverage digital technology to better manage their health.
An opportunity for charitable pharmacies to collaborate with oncology practices for non-oncology medications during and after treatment.
Federal/state grants are not the only gateways to funding. There are close to 750 “community foundations” nationwide which are public charities dedicated to improving the lives of people in a defined local geographic area.
The five most recent states to expand the scope of reimbursement for pharmacists are Maryland, Missouri, North Dakota, Virginia and Wyoming
Good Pill will provide direct access to hundreds of life-saving medications and save families $150+/month on healthcare cost
NOVA ScriptsCentral is excited to collaborate with the American Pharmacist Association to launch the “NOVA ScriptsCentral & American Pharmacist Association Safety-Net Health Equity Fellowship”.
FDA approves 1 Year delay of Track & Trace requirements
How Many People Might Lose Medicaid When States Unwind Continuous Enrollment?
An opportunity for charitable pharmacies to collaborate with oncology practices for non-oncology medications during and after treatment.
St. Vincent de Paul Charitable Pharmacy offers article regarding impact of a charitable pharmacy on their community and patients
The Outcomes of Implementing and Integrating Comprehensive Medication Management in Team-Based Care: A Review of the Evidence on Quality, Access and Costs, December 2023

